Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -22.61M | -15.52M | -12.73M | -12.27M | -5.58M |
| Total Depreciation and Amortization | 36.55M | 36.94M | 36.37M | 36.71M | 43.33M |
| Total Amortization of Deferred Charges | 648.30K | 648.30K | 648.30K | 648.30K | 478.10K |
| Total Other Non-Cash Items | 25.78M | 23.26M | 20.31M | 22.33M | 2.58M |
| Change in Net Operating Assets | -1.39M | 1.28M | 1.70M | -20.84M | -22.53M |
| Cash from Operations | 38.98M | 46.61M | 46.29M | 26.58M | 18.28M |
| Capital Expenditure | -1.77M | -1.67M | -1.28M | -702.60K | -2.03M |
| Sale of Property, Plant, and Equipment | 1.46M | 1.46M | 1.46M | 1.41M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.11M | 15.99M | 10.14M | 21.23M | -22.53M |
| Cash from Investing | -2.43M | 15.78M | 10.31M | 21.94M | -24.56M |
| Total Debt Issued | 2.93M | 4.00M | 4.69M | 4.80M | 56.16M |
| Total Debt Repaid | -25.65M | -25.97M | -23.94M | -22.82M | -23.66M |
| Issuance of Common Stock | 957.00K | 597.00K | 362.00K | 380.00K | 397.00K |
| Repurchase of Common Stock | -22.80M | -30.16M | -42.87M | -53.38M | -42.98M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.32M | -9.67M | -10.18M | -9.88M | -7.15M |
| Cash from Financing | -39.57M | -45.07M | -53.21M | -59.84M | -13.00M |
| Foreign Exchange rate Adjustments | 341.70K | 17.00K | 1.74M | 2.00M | 1.47M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.68M | 17.33M | 5.14M | -9.32M | -17.81M |
